Jaka jest cena za Mymetics Corporation (MYMX)

Cena za Mymetics Corporation (MYMX) wynosi $0.0003

Jaka jest kapitalizacja rynkowa dla Mymetics Corporation (MYMX)

Kapitalizacja rynkowa dla Mymetics Corporation (MYMX) wynosi $46.00

Przychody Mymetics Corporation (MYMX)

Mymetics Corporation is a Swiss biotechnology company dedicated to the research and development of vaccines aimed at preventing infectious and debilitating diseases. Its robust pipeline features several promising vaccine candidates, including those for HIV-1/AIDS, COVID-19, intranasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya. The company actively collaborates with leading institutions such as the Texas Biomedical Research Institute, the PATH Malaria Vaccine Initiative, and the National Institute of Allergy and Infectious Diseases' Laboratory of Malaria Immunology and Vaccinology, focusing on the development and production of virosome-based vaccine formulations for a malaria transmission-blocking agent. Additionally, Mymetics works with Sanofi Pasteur Biologics, LLC to assess the immunogenicity of influenza vaccines. Founded in 1990, the company was formerly known as ICHOR Corporation, adopting its current name in July 2001, and maintains its base of operations in Epalinges, Switzerland.

Rok	Przychody	Zmień
Za mało danych dla podanych dat.

Rok

Przychody

Zmień

Za mało danych dla podanych dat.

Firma	Przychody	Różnica w przychodach	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	$10.11B	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Firma

Przychody

Różnica w przychodach

Kraj